Better Cancer Treatment with Liposome-Entrapped Adriamycin
Author Information
Author(s): A. Gabizon, D. Goren, Z. Fuks, A. Meshorer, Y. Barenholz
Primary Institution: Hadassah University Hospital
Hypothesis
Can liposome-entrapped Adriamycin improve anti-tumor activity compared to free Adriamycin in a murine metastatic tumor model?
Conclusion
Liposome-entrapped Adriamycin significantly improves survival and tumor remission in mice with liver metastases compared to free Adriamycin.
Supporting Evidence
- Liposome-entrapped Adriamycin increased survival time by 42-116% compared to free Adriamycin.
- Complete pathological remission was observed in 9 out of 12 mice treated with liposome-entrapped Adriamycin.
- Histopathological studies showed extensive regression of tumor foci in the liver and spleen with liposome-entrapped Adriamycin.
Takeaway
Using special tiny bubbles called liposomes to carry a cancer drug makes it work much better in fighting tumors in mice.
Methodology
Mice were treated with either liposome-entrapped Adriamycin or free Adriamycin, and their survival and tumor response were monitored.
Limitations
The study primarily focused on a specific tumor model and may not generalize to all types of cancers.
Participant Demographics
BALB/c mice, age- and sex-matched.
Statistical Information
P-Value
<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website